Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia
Seyam, S., Razein, H., Nair, U., Elkousy, I. (2022). Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia. EKB Journal Management System, 4(6), 2426-2432. doi: 10.21608/ijma.2022.145859.1471
Sameh Seyam; Hassan Razein; Unni Nair; Islam Elkousy. "Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia". EKB Journal Management System, 4, 6, 2022, 2426-2432. doi: 10.21608/ijma.2022.145859.1471
Seyam, S., Razein, H., Nair, U., Elkousy, I. (2022). 'Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia', EKB Journal Management System, 4(6), pp. 2426-2432. doi: 10.21608/ijma.2022.145859.1471
Seyam, S., Razein, H., Nair, U., Elkousy, I. Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia. EKB Journal Management System, 2022; 4(6): 2426-2432. doi: 10.21608/ijma.2022.145859.1471

Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia

International Journal of Medical Arts
Article 5, Volume 4, Issue 6, June 2022, Page 2426-2432  XML PDF (1.06 MB)
Document Type: Original Article
DOI: 10.21608/ijma.2022.145859.1471
View on SCiNiTO View on SCiNiTO
Authors
Sameh Seyam email 1; Hassan Razein2; Unni Nair3; Islam Elkousy4
1Department of Anesthesia and Intensive Care, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
2Department of Pulmonology, Zulekha Hospital, Dubai, United Arab Emirates
3Department of Internal Medicine, Zulekha Hospital, Dubai, United Arab Emirates
4Department of Critical Care, Zulekha Hospital, Dubai, United Arab Emirates
Abstract
Background: Ventilator-associated pneumonia [VAP] is a type of infection affecting the lower part of the respiratory system related to the intubation of trachea.
Patients and methods: An observational randomized prospective study approved by the ethical committee of Mustasharak Hospital, Saudi Arabia, and was conducted in the period from June 2021 to May 2022. Patients were randomly categorized into two primary groups using a randomized and computer-generated table. The first group [group NI; n=31] received intravenous and nebulized amikacin, while the second group [group [I]; n=31] and only received intravenous amikacin.
Result: Pseudomonas infection accounted for about 65% of patients in group NI, and 40% in group I. Klebsiella infection was 30% in group NI, and 25% in group I. Acinetobacter infection was approximately 15% in group NI and 40% in group I. The Clinical Pulmonary Infection [CPI] score for group NI was ≤ 6 in 73% of patients. In group I, the CPI score was ≤ 6 in 54%. Oxygenation within Group NI significantly improved before, and after treatment [p 0.005]. However, in group I, no change was discovered [p 0.209]. Creatinine level was significantly high in group I after treatment.
Conclusion: Nebulized amikacin is considered a safe and effective treatment option for VAP.
Keywords
Ventilator; Pneumonia; Infection; Amikacin
Statistics
Article View: 286
PDF Download: 151